Why did GAAP net income jump so much versus last year?

Q3 2024 GAAP net income of $0.7 billion included a one-time, non-cash after-tax investment loss of $1.0 billion. Q3 2025 had no comparable charge, and net investment gains were a positive contributor, so GAAP EPS rose to $6.98 from $2.63. Adjusted EPS, which strips out these items, was more modest at $7.83 versus $7.51.

Is Cigna still on track to meet its 2025 earnings guidance?

Yes. Cigna reaffirmed its full-year 2025 adjusted income from operations outlook of at least $29.60 per share. Year to date through nine months, adjusted EPS was $21.76, implying the remaining quarter needs roughly $7.84 per share to hit the target. Note that guidance excludes future special items and investment results, which can vary.

Why did Cigna Healthcare's profitability decline?

Cigna Healthcare's adjusted pre-tax income fell 12%, mainly because the medical care ratio rose to 84.8% from 82.8%. The increase was attributed to the Individual and Family Plans business and higher stop-loss medical costs, which management said were consistent with its expectations. Segment revenue fell 18% largely due to the March 2025 sale of Medicare businesses to HCSC, though it grew 6% excluding that divestiture.

What is the new rebate-free pharmacy benefit model and why does it matter?

Cigna announced a rebate-free pharmacy benefit model designed to lower costs, improve transparency, and support local pharmacies. The press release does not quantify its financial impact, timing, or effect on Evernorth's revenues and margins. Investors should look for details on the rollout and expected financial effects in future earnings calls and filings, as rebate changes can materially affect pharmacy benefit manager revenue and margin profiles.

Which segment is driving growth, and where are the pressure points?

Evernorth Health Services is the growth engine, with adjusted revenues up 15%, driven by strong specialty volume and pharmacy benefit growth. Pressure points include Pharmacy Benefit Services profit, which fell 6% due to strategic investments, and Cigna Healthcare, where elevated medical costs compressed margins. Specialty and Care Services, which benefited from biosimilar adoption, was a bright spot with profit up 11%.

CI 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) reported third quarter 2025 results on October 30, 2025, with total revenues up 10% year over year to $69.7 billion^a, driven primarily by Evernorth Health Services and strong specialty pharmacy growth.

GAAP shareholders' net income was $1.9 billion^b, or $6.98 per share, versus $0.7 billion, or $2.63 per share, in the prior-year quarter, which included a $1.0 billion after-tax investment loss. Adjusted income from operations was $2.1 billion, or $7.83 per share, roughly flat with the $7.51 reported a year earlier, and adjusted operating income declined 1% year over year. The segment picture is mixed.

Evernorth Health Services grew adjusted revenues 15%^c and adjusted pre-tax income 1%, with Pharmacy Benefit Services revenues up 18% but profit down 6% due to strategic investments, while Specialty and Care Services profit rose 11%. Cigna Healthcare faced pressure: adjusted pre-tax income fell 12% and the medical care ratio rose to 84.8% from 82.8%, driven by the Individual and Family Plans business and higher stop-loss costs. Adjusted revenues in that segment fell 18% largely because of the March 2025 divestiture of Medicare businesses to HCSC, though growth was 6% excluding that impact.

Management reaffirmed full-year 2025 adjusted EPS of at least $29.60^d and guided to Cigna Healthcare MCR of 83.2% to 84.2%. The company also announced a new rebate-free pharmacy benefit model, which is a strategic initiative that could affect future Evernorth economics and warrants monitoring for its financial impact.

02—Key points

Key Highlights

Total revenues rose 10% to $69.7 billion in Q3 2025, led by Evernorth Health Services and specialty pharmacy growth.
GAAP shareholders' net income was $1.9 billion ($6.98/share), up sharply from $0.7 billion ($2.63/share) in Q3 2024, which had a $1.0 billion one-time investment loss.
Adjusted income from operations was $2.1 billion ($7.83/share), roughly flat year over year versus $7.51/share, and down 1% on an adjusted basis.
Full-year 2025 adjusted EPS outlook of at least $29.60 was reaffirmed, with Evernorth pre-tax adjusted income guided to at least $7.2 billion and Cigna Healthcare to at least $4.125 billion.
Cigna Healthcare's medical care ratio worsened to 84.8% from 82.8%, driven by Individual and Family Plans and higher stop-loss costs; full-year MCR guidance is 83.2% to 84.2%.
Evernorth's Pharmacy Benefit Services adjusted revenues grew 18%, but pre-tax profit fell 6% amid strategic investments, while Specialty and Care Services profit rose 11%.
Management announced a new rebate-free pharmacy benefit model intended to lower costs and improve transparency, a potentially significant structural change to Evernorth's business model.

03—Questions

Frequently Asked Questions

Why did GAAP net income jump so much versus last year?
Q3 2024 GAAP net income of $0.7 billion included a one-time, non-cash after-tax investment loss of $1.0 billion. Q3 2025 had no comparable charge, and net investment gains were a positive contributor, so GAAP EPS rose to $6.98 from $2.63. Adjusted EPS, which strips out these items, was more modest at $7.83 versus $7.51.
Is Cigna still on track to meet its 2025 earnings guidance?
Yes. Cigna reaffirmed its full-year 2025 adjusted income from operations outlook of at least $29.60 per share. Year to date through nine months, adjusted EPS was $21.76, implying the remaining quarter needs roughly $7.84 per share to hit the target. Note that guidance excludes future special items and investment results, which can vary.
Why did Cigna Healthcare's profitability decline?
Cigna Healthcare's adjusted pre-tax income fell 12%, mainly because the medical care ratio rose to 84.8% from 82.8%. The increase was attributed to the Individual and Family Plans business and higher stop-loss medical costs, which management said were consistent with its expectations. Segment revenue fell 18% largely due to the March 2025 sale of Medicare businesses to HCSC, though it grew 6% excluding that divestiture.
What is the new rebate-free pharmacy benefit model and why does it matter?
Cigna announced a rebate-free pharmacy benefit model designed to lower costs, improve transparency, and support local pharmacies. The press release does not quantify its financial impact, timing, or effect on Evernorth's revenues and margins. Investors should look for details on the rollout and expected financial effects in future earnings calls and filings, as rebate changes can materially affect pharmacy benefit manager revenue and margin profiles.
Which segment is driving growth, and where are the pressure points?
Evernorth Health Services is the growth engine, with adjusted revenues up 15%, driven by strong specialty volume and pharmacy benefit growth. Pressure points include Pharmacy Benefit Services profit, which fell 6% due to strategic investments, and Cigna Healthcare, where elevated medical costs compressed margins. Specialty and Care Services, which benefited from biosimilar adoption, was a bright spot with profit up 11%.

04—Continue

← View all 8-K filings